Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in ...

This recent readout follows successful data from another combination including Braftovi in mCRC.

In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating ...

A new report shows better than 80% concordance between liquid biopsy and tissue biopsy. Liquid biopsy and analysis of circulating tumor DNA (ctDNA) is a viable option for determining the presence of ...

Tumor Promotion in BRAF Wild-Type Tumors: In vitro experiments have demonstrated paradoxical activation of MAP-kinase signaling and increased cell proliferation in BRAF wild-type cells exposed to BRAF ...

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...

Pfizer announces positive results from pivotal BREAKWATER trial of Braftovi in combo with cetuximab & Folfiri in patients with metastatic colorectal cancer: New York Wednesday, Fe ...

NEW YORK, Sept 14 (Reuters) - Pfizer (PFE.N), opens new tab is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the ...

BRAF is the most commonly mutated gene associated with melanoma, found in more than 50 percent of patients. The gene encodes a cytoplasmic kinase that is a member of the MAPK signal-transduction ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...